June 12, 2018 Newport Coast CA – VivoSense (Vivonoetics), the leading provider of visualization and analysis software for data from wearable sensors is excited to announce the release of VivoSense® 3.2.
With the accelerating adoption of wearable physiological sensors, large complex clinical trial data sets are being generated across a wide variety patient populations and disease states, including rare diseases. VivoSense® 3.2 provides the most rigorous analyses of these data possible in providing the endpoints and biomarkers which withstand Regulatory scrutiny and academic oversight.
If you have VivoSense® 3.0 or greater, please install the latest version, or request a free trial license.
As a company VivoSense is committed to providing robust clinical endpoints for industry leading biotechnology, pharma, CROs and healthcare providers including Roche, Mayo Clinic, Nationwide Children’s Hospital and Harvard University.
Dudley Tabakin
Dudley Tabakin, MSc. is Chief Product Officer and co-founder of VivoSense and a fervent believer in “good data” over “big data” in the development of digital endpoints from wearable sensor technology.
LinkedIn Profile for VivoSense Releases Newest Enhanced Wearable Sensor Analysis Platform